We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Bruker Corporation
Health Care · Life Sciences Tools & Services
4B revenue split across BSI Life Science (mass spec + NMR + spatial biology), BSI NANO (microscopy + semi metrology + X-ray), and BSI CALID, plus a small BEST superconductor segment. Spatial biology rollup (NanoString CosMx, Canopy, PhenoImager) repositions BRKR from instruments-only to instruments + consumables in the fastest-growing slice of biopharma R&D.
- timsTOF mass spec franchise compounding double-digits; differentiated 4D proteomics vs $TMO Orbitrap
- Spatial biology TAM ($3-5B by 2030) with installed-base + consumable pull-through after NanoString deal
- Semi/applied exposure via Nano segment levers $ASML/$AMAT capex cycle without pure-cyclical beta
- Owner-operator culture (Laukien family ~25%) - long capital-allocation horizon vs peers
- Pharma R&D budget freeze + China academic funding cuts pressure 2025-2026 instruments orders
- Spatial biology M&A stack lifted leverage (~2.5x net debt/EBITDA) ahead of integration risk
- Gross margins (~50%) structurally below $TMO/$DHR (~55-60%) - consumables mix shift slow
- NIH/academic exposure (~30% of life-sci revenue) is policy-sensitive into US budget cycle
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.